The round was led by Senator Investment Group with participation from Section 32, Korea-based Partners Investment, and Eli Lilly.

Investors in AltPep's Series A round, including Alexandria Venture Investments and Matrix Capital Management Company also participated in the Series B round.

AltPep said that the proceeds from the round will be used to accelerate its Sobin therapeutics for both Alzheimer's and Parkinson's diseases into phase I clinical trials, as well as to advance its Soba diagnostic blood-based assay for Alzheimer's disease with the aim of obtaining a U.S. Food and Drug Administration (FDA) clearance.

The Soba diagnostic test, which has received FDA breakthrough device designation, targets toxic soluble oligomers, which are early molecular triggers for the disease.

In conjunction with the financing, Rohit Vanjani of Senator Investment Group will be appointed to AltPep's board of directors, and Ronald DeMattos, senior vice president and chief scientific officer for neurobiologicals at Lilly, will join AltPep's Scientific Advisory Board.

Gut bacteria changes in preclinical Alzheimer’s suggest ways to detect, delay disease
People with pre-symptomatic Alzheimer’s disease have different gut bacteria than healthy individuals, suggesting the microbiome could be used to detect...

Alzheimer’s drug could prevent damage to the brain
Researchers showed that tiny aggregates of amyloid beta protein, a naturally occurring substance associated with Alzheimer’s disease progression, can...

Novel peptide targets Alzheimer’s disease years before symptoms
New research demonstrates a novel synthetic peptide’s ability to selectively detect and neutralize an early molecular trigger of Alzheimer’s disease,...

Mutated protein causes Parkinson's, protects against MSA
A single change in the misfolding protein that causes Parkinson's disease can protect against multiple system atrophy (MSA), University of Massachusetts...